Iron-binding ligands, such as DFO and Dp44mT, inhibit the TGF-β-induced EMT via NDRG1 up-regulation, providing a potential therapeutic strategy to inhibit tumor metastasis [36,82]. This evidence concerns the gene TGFB1 and neoplasm.